You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the BRUKINSA (zanubrutinib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR BRUKINSA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for BRUKINSA

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03145064 ↗	Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma	Completed	BeiGene	Phase 2	2017-06-30	Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.
NCT03332017 ↗	A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma	Active, not recruiting	BeiGene	Phase 2	2017-11-15	The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.
NCT03336333 ↗	A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL	Recruiting	BeiGene	Phase 3	2017-11-02	To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for BRUKINSA

Condition Name

Chart
Table

Condition Name for BRUKINSA
Intervention	Trials
Small Lymphocytic Lymphoma	3
Refractory Transformed B-Cell Non-Hodgkin Lymphoma	2
Diffuse Large B-cell Lymphoma	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for BRUKINSA
Intervention	Trials
Lymphoma	17
Leukemia, Lymphocytic, Chronic, B-Cell	7
Lymphoma, B-Cell	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for BRUKINSA

Trials by Country

Map
Table

Trials by Country for BRUKINSA
Location	Trials
United States	92
China	27
Australia	22
France	14
Japan	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for BRUKINSA
Location	Trials
Texas	7
Illinois	6
Florida	6
Nevada	5
New York	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for BRUKINSA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for BRUKINSA
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	1
Phase 2	16
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for BRUKINSA
Clinical Trial Phase	Trials
Not yet recruiting	12
Recruiting	10
Completed	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BRUKINSA

Sponsor Name

Chart
Table

Sponsor Name for BRUKINSA
Sponsor	Trials
BeiGene	17
National Cancer Institute (NCI)	4
Peking Union Medical College Hospital	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for BRUKINSA
Sponsor	Trials
Industry	21
Other	14
NIH	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.